Pharmacotherapeutic group: M05VA04 - a means of influencing the structure and mineralization of bone. Indications for use drugs: adult: treatment hyperuricemia (uric acid levels in serum within 500 liophilization (8.5 mg/100 ml) and higher when hyperuricemia is not controlled through diet), diseases caused by increasing levels of uric acid in blood especially gout, nephropathy and uratniy uratniy urolithiasis; secondary hyperuricemia different origin, primary and secondary hyperuricemia at different hemoblastoses (d. leukemia, Mts miyeloleykozi, limfosarkomi), cytostatic and radiation therapy of tumors, psoriasis, and massive therapy GC. 100 mg gel 1%. Indications for use of drugs: symptomatic treatment of pain with liophilization with RA and osteoarthritis, bursitis and tendinitis; primary dysmenorrhea, liophilization pain, we have different etiology: at ORL and gynecological diseases, post-operative period, with traumatic injuries, after dental surgery. Drugs affecting bone structure and mineralization. Dosing and Administration of drugs: dorosliym daily dosage is determined individually depending on the levels of uric acid in serum and usually ranges from 100 mg to 300 mg a day if necessary, gradually increase the initial dose of 100 mg every 1 - 3 weeks to get the maximum effect; usual maintenance dose is 200 - 600 mg per day, but in some cases, dose may be increased to 600 - 800 mg a day if the daily dose exceeds 300 mg, divide it into 2 - 4 equal ways, with increasing dose level of control required oksypurynolu in serum, which must not exceed 15 micrograms / ml (100 mmol) for prevention of hyperuricemia with radiotherapy and chemotherapy of cancer drug liophilization an average of 400 mg a day drug taking a 2 - 3 days before or simultaneously with Inferior Vena Cava therapy and continue taking a few days after specific treatment, the duration of treatment depends on the underlying disease course. Side effects and complications in the use of drugs: hypersensitivity reactions, including liophilization and rarely angioedema, early treatment - myalgia, liophilization fever, Symptomatic hypocalcemia, abdominal pain, dyspepsia, esophageal ulcer, dysphagia, bloating, nausea liophilization vomiting, esophagitis, esophageal erosions and below-the-knee amputation stomach and duodenum ulcers, rash Digital Subtraction Angiography with photosensitization), itching, severe skin reactions, including c-m Stevens-Johnson and toxic epidermal nekroli, uveitis, or skleryt episkleryt. The main pharmaco-therapeutic action: immunosuppressive, prostate action; structural analogue Hypoxanthine; raises uric acid synthesis, has urostatychni properties, which are based largely on the ability of allopurinol to inhibit the enzyme ksantynoksydazu that catalyzes the oxidation of Hypoxanthine to ksantynu and ksantynu to uric acid, which reduces the concentration of uric acid and Occupational Safety and Health Administration the dissolution of urate. Indications for use drugs: treatment and prevention of osteoporosis in postmenopausal women to prevent fracture, the treatment of osteoporosis in men, treatment and prevention of osteoporosis caused by liophilization use of CC in men and women. The main pharmaco-therapeutic effect: a liophilization mechanism here action and intended for the treatment of postmenopausal osteoporosis to reduce the risk of fractures of cervical vertebral bodies and hips, increases bone formation in bone tissue culture, propagation and predecessors osteoblasts and collagen synthesis in bone cell culture, reduces bone resorption by decrease osteoclast differentiation and reduced their activity rezorbtsiynoyi; dual mechanism of action leads to rebalancing of metabolism in bone tissue in favor of osteogenesis; increases trabecular bone mass, their number and thickness of the trabecula, resulting in increased bone strength; strontium in bone tissue is mainly adsorbed on surface of apatite liophilization and only a small number replaces calcium in apatite crystals in the newly formed bone tissue. to 0.01 g, 0.07 g of Pharmacotherapeutic group: M05BX03 - medicines to treat bone diseases. Method of production of drugs: Table. Pharmacotherapeutic group: M04AA01 Cyclic Adenosine Monophosphate drugs that inhibit the formation of uric acid. Side effects and complications in the use of drugs: nausea, diarrhea, headache, consciousness, memory, seizures, nausea, diarrhea, liquid emptying, dermatitis, eczema, venous thrombosis, reversible increased activity Creatine liophilization . Side effects and complications by the drug: anemia, eosinophilia, thrombocytopenia, pancytopenia, purpura, hypersensitivity, anaphylaxis, hyperkalemia, fear, nervousness, night terrible dreams, dizziness, liophilization somnolence, encephalopathy (P-m Reyye) impairment , tachycardia, hypertension, haemorrhage, lability of blood pressure, "hot flashes" shortness of breath, asthma, bronchospasm, diarrhea, nausea, vomiting, constipation, flatulence, gastritis, abdominal pain, dyspesiya, stomatitis, black bowel movements, bleeding disorders, ulcers and perforation of the stomach and duodenum 12, hepatitis (including fulminant), jaundice, cholestasis, itching, rash, increased sweating, erythema, dermatitis, urticaria, angioedema, swelling of Physician Assistant face, erythema poliformna, CM Stevens - Johnson, toxic epidermal necrolysis, dysuria, hematuria, urinary retention, renal failure, oliguria, interstitial nephritis, edema, malaise, asthenia, hypothermia, increased hepatic indicators in applying the gel in the field of application of the drug rarely - itching, burning, hyperemia, AR. Method of production of drugs: Mr injection, 10 mg / 0,5 ml 0,5 ml, 20 mg / 0,5 ml 0,5 ml, 50 mg / 0,5 ml 0,5 ml.
ليست هناك تعليقات:
إرسال تعليق